Intraperitoneal perfusion of endostatin improves the effectiveness and prolongs the prognosis of patients with gastric cancer

doi:10.4251/wjgo.v17.i4.103131

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 4

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (138)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-2) series, Tables (1-5) series.

Item

Count

PDF

HTML

Figures (1-2)

Tables (1-5)

Sum=109

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=18

Apr 15, 2025 (publication date) through Mar 28, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Clinical Trials Study

World J Gastrointest Oncol. Apr 15, 2025; 17(4): 103131
Published online Apr 15, 2025. doi: 10.4251/wjgo.v17.i4.103131

Table 2 Comparison of the treatment efficacy in patients in the two groups, n (%)

Variables	Total (n = 115)	Control group (n = 56)	RH-endostatin group (n = 59)	χ²	P value
CR	19 (16.5)	8 (14.3)	11 (18.6)
PR	50 (43.5)	20 (35.7)	30 (50.8)
SD	20 (17.4)	12 (21.4)	8 (13.7)
PD	26 (22.6)	16 (28.6)	10 (16.9)
ORR	69 (60.0)	28 (50.0)	41 (69.4)	4.548	0.033
DCR	89 (77.4)	40 (71.4)	49 (83.1)	2.218	0.136

CR: Complete remission; PR: Partial remission; SD: Stable disease; PD: Progressive disease; ORR: Overall remission rate; DCR: Disease control rate; RH-endostatin: Recombinant human endostatin.

Citation: Liu Y, Liu HG, Zhao C. Intraperitoneal perfusion of endostatin improves the effectiveness and prolongs the prognosis of patients with gastric cancer. World J Gastrointest Oncol 2025; 17(4): 103131
URL: https://www.wjgnet.com/1948-5204/full/v17/i4/103131.htm
DOI: https://dx.doi.org/10.4251/wjgo.v17.i4.103131